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considered for high-risk patients who do not achieve optimal low-density lipoprotein
cholesterol lowering on statin monotherapy or who are statin intolerant. Changes in fasting
serum glucose (FSG) levels during ezetimibe, ezetimibe/statin, and statin treatments were
assessed using data pooled from clinical trials in hypercholesterolemic and heterozygous
familial hypercholesterolemic patients, who were or were not receiving statin therapy.
Study types included ﬁrst-line trials in statin-naive/wash-out patients and second-line add-
on and uptitration studies in patients on stable statin therapy. Similar analyses of FSG
changes were performed separately for each study type in patients who were nondiabetic at
baseline. Across all study types and treatments, mean FSG increases from baseline were
small (0.5 to 3.7 mg/dl with ezetimibe/statin; 0.2 to 4.6 mg/dl with statins) and decreased
over time; between-treatment differences (0.3 to 1.4 mg/dl) were nonsigniﬁcant for all
comparisons. Proportions of patients with elevated FSG ‡126 mg/dl during therapy were
low and similar for all treatments in the overall cohort (1.2% to 4.3%). Elevations were
highest (3.3% to 25.7%) among patients with baseline factors characteristic of metabolic
syndrome and prediabetes, including higher FSG, body mass index, and triglyceride levels,
and numerically lower baseline high-density lipoprotein cholesterol; however, these factors
were not related to FSG increases. Changes in low-density lipoprotein cholesterol, body
mass index, high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B were
not signiﬁcantly correlated with FSG increases. In conclusion, statin therapy was associated
with small FSG increases, and the addition of ezetimibe did not further increase FSG levels
beyond those of statins when given to patients who are statin naive or those on statin
therapy.  2016 The Authors and Merck Sharp & Dohme Corp. Published by Elsevier
Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2016;118:1812e1820)Some studies have indicated that statins are associated
with an increased risk of developing diabetes mellitus and
increased insulin resistance, especially at higher doses of
some statins.1e3 The Food and Drug Administration
recently added warnings of increased glycosylated hemo-
globin A1c (HbA1c) and fasting serum glucose (FSG) levels
to statin labels.4 However, the risk was said to be small, and
the cardiovascular beneﬁts of statins outweigh this small
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Preventive Cardiology/Glucose Changes With Ezetimibe/Statin in Hypercholesterolemia 1813ezetimibe þ simvastatin, and statin treatment using data
pooled from randomized clinical studies in patients who are
nondiabetic, hypercholesterolemic, and heterozygous fa-
milial hypercholesterolemic (HeFH) and were or were not
receiving statin therapy at study start.
Methods
Changes in FSG were assessed in ﬁrst-line short- and
long-term studies and second-line add-on and uptitration
studies pooled separately in hypercholesterolemic patients
without diabetes at baseline. Studies included in the ana-
lyses are described in Supplementary Table 1. The ﬁrst-line
(statin naive) analyses included 7 similarly designed studies
of up to 12 weeks in duration and 3 long-term studies,
including 2 studies in hypercholesterolemic patients (1A and
1B; 26- and 60-week durations, respectively) and 1 in HeFH
patients (II; 96 weeks duration). Two studies were included
in the second-line add-on analysis with treatment durations
up to 8 weeks and 3 studies were included in the second-line
uptitration analysis with duration up to 12 weeks.
Treatment comparisons performed were pooled across
studies (where applicable). First-line short-term studies were
pooled across statin brands and doses, and treatment with
ezetimibe 10 mg versus placebo, statins versus placebo, and
ezetimibe combined with statins versus statins was
compared. For the ﬁrst-line long-term studies, 2 separate
analyses were conducted: one for studies IA and IB pooled
across statin doses that compared ezetimibe/all simvastatin
versus simvastatin and study II that compared ezetimibe/
simvastatin 80 mg versus simvastatin 80 mg. The second-
line add-on studies were pooled across statin brand and
doses and compared statin versus ezetimibe added to a
statin. The second-line uptitration studies compared statin
uptitration versus ezetimibe combined with a statin. End
points assessed for all studies included change from baseline
in mean FSG, proportions of patients with baseline FSG
<126 mg/dl who had FSG 126 mg/dl during treatment,
associations between prespeciﬁed baseline covariates and
changes in FSG, and correlations between change from
baseline in prespeciﬁed variables and FSG changes.
The ﬁrst-line short- and long-term and second-line add-
on and uptitration analyses were performed separately for
each study type and were generally similar. For both ﬁrst-
line and second-line studies, mean FSG values at baseline,
post-baseline, and mean change from baseline were sum-
marized. Mean change from baseline to a given time point
for ﬁrst-line and second-line studies was estimated using a
longitudinal data analysis (LDA) model that handled both
repeated-measures and missing data.12 The model included
both baseline and post-baseline measurements as response
variables and terms for trial, treatment, statin dose (when
appropriate), time (categorical variable), and interaction of
time by treatment, with a restriction of the same baseline
mean across treatment groups (because of randomization).
An unstructured covariance matrix was used to model the
correlation among repeated measurements. Between-
treatment differences were also estimated from the model.
Summary statistics of baseline characteristics (age,
gender, race, body mass index [BMI], FSG, LDL-C, tri-
glycerides, high-density lipoprotein cholesterol [HDL-C],and total cholesterol) for subjects with and without post-
baseline FSG values 126 mg/dl were provided. The pro-
portion of subjects with baseline FSG values <126 mg/dl
who had an FSG value 126 mg/dl during treatment was
analyzed using adjusted odds ratios, 95% conﬁdence in-
tervals [CIs], and p values. The analysis was performed
using the earlier mentioned LDA model to impute missing
data within study time frames. Subjects were categorized as
having either an elevated FSG measurement (FSG
126 mg/dl) or not at each time point after imputations. To
estimate the odds ratio, imputed data sets were analyzed by
a logistic regression model that included terms for treatment,
baseline FSG, and study (when appropriate); the odds ratios
for treatment comparisons were combined using Rubin’s
formula.13 For the long-term studies that had differing time
points, a separate analysis was performed for each study,
and therefore, study was not included in the model.
Analysis of the proportion of subjects with FSG
126 mg/dl was additionally performed in the subgroups of
subjects who had baseline FSG values <100 mg/dl and from
100 to 126 mg/dl. An analysis on the proportion of subjects
with baseline FSG <126 mg/dl who had FSG 126 mg/dl
during the treatment period without imputing the missing
data was performed as a sensitivity analysis. Scatter plots of
the values for the various baseline characteristics versus
maximum FSG values were also produced.
The association between prespeciﬁed baseline covariates
(study, statin brand, potency, age, gender, race, BMI, and
baseline FSG, triglycerides, and HDL-C) and FSG changes
was evaluated by univariate analyses using the LDA model
with change from baseline as the dependent variable and
each covariate as the independent variable. The placebo
group was excluded from the covariate analysis as values for
potency and statin brand were missing for this treatment.
Parameter estimates, 95% CIs, and p values from the model
were reported. All covariates with p <0.05 were further
explored in a multivariable model using the LDA approach.
Associations between post-baseline changes in BMI, LDL-C,
apolipoprotein (Apo) B, HDL-C, and triglycerides and FSG
changes was evaluated by simple linear regression to provide
estimates of slope, intercept, and R-square. Correlation
values and the corresponding 95% CIs and p values were
provided. Scatterplots were generated to explore the nature
(direction) and/or strength of any potential relation with FSG
changes for both analyses.
Results
A total of 4,726 subjects were included in the full analysis
cohort of pooled, ﬁrst-line short-term studies. The full
analysis cohort of pooled, ﬁrst-line long-term studies (up to
96 weeks) included 2,041 subjects. A total of 1,295 subjects
were included in the full analysis cohort of pooled, second-
line uptitration studies, and 2,357 subjects were included in
the full analysis cohort of pooled second-line add-on studies.
Baseline characteristics were generally similar between the
treatment groups in the ﬁrst-line short- and long-term studies
and in the second-line add-on study and uptitration study
types with some exceptions (Supplementary Table 2). Mean
ages were slightly lower in the ﬁrst-line long-term study II
(46 years) and somewhat higher in the second-line add-on
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Figure 1. Changes in FSG over time in ﬁrst-line statin-naive cohorts. Error
bars represent SE. (A) Short-term studies. *p <0.05 at week 2 for statin and
ezetimibe 10 mg (Eze) þ statin groups, and †p <0.05 from weeks 2 to 4 for
statin group for within-treatment group FSG increases. zp <0.05 for within-
treatment group decrease in FSG from week 8 to 12 for placebo (PBO) and
statin. Statin ¼ simvastatin (10, 20, 40, or 80 mg), lovastatin (10, 20, or
40 mg), pravastatin (10, 20, or 40 mg), and atorvastatin (10, 20, 40, or
80 mg). (B) Long-term studies with the All Simva, Eze/Simva, Simva
80 mg, and Eze/Simva 80 mg treatment groups. All Simva ¼ simvastatin
(10, 20, 40, or 80 mg), Eze/Simva ¼ Eze 10 mg/Simva (10, 20, 40, or
80 mg).
1814 The American Journal of Cardiology (www.ajconline.org)(61 years) and uptitration (67 years) studies than in the
ﬁrst-line studies IA and IB (56 years). Mean baseline LDL-C
was 178 mg/dl in ﬁrst-line studies but was higher in
long-term study II in HeFH patients (318 mg/dl), and lower
in second-line add-on (137 mg/dl) and uptitration studies
(102 mg/dl). Mean triglyceride levels were somewhat higher
in ﬁrst-line studies (156 mg/dl) than in the second-line
add-on (142 mg/dl) and uptitration studies (119 mg/dl).
Mean FSG values were (94 mg/dl) for ﬁrst-line studies but
slightly lower for ﬁrst-line long-term study II (89 mg/dl) and
were somewhat higher for second-line add-on and uptitration
studies (98 mg/dl).
Mean FSG changes from baseline were overall small for
all study types and treatments. The mean FSG values at post-
treatment time points were similar for statin and ezetimibe/
statin groups. In the ﬁrst-line studies, the range in FSG levels
for post-treatment time points was 96 to 97 mg/dl in both the
short-term studies and the long-term studies IA þ IB and 90
to 93 mg/dl for the long-term study II. Post-treatment FSG
levels in the second-line studies were 98 mg/dl for add-on
and 99 mg/dl for uptitration study types. In the ﬁrst-line
short-term studies, changes from baseline in ezetimibe
monotherapy were very small and comparable with placebo
(0.5 to 0.6 mg/dl for both) during 12 weeks. For the pooled
statin and ezetimibe þ statin treatment groups, a statistically
signiﬁcant increase from baseline in mean FSG was
observed by week 2 that continued to increase through week
8 and then decreased at week 12 (Figure 1). The maximum
increase over the 12-week period occurred at week 8 and
was 2.0 mg/dl (95% CI 1.4, 2.5) for the pooled statin and
1.7 mg/dl (95% CI 1.1, 2.2) for the ezetimibe þ pooled statin
treatment groups. At week 12, the pooled statin group
showed a signiﬁcantly higher increase from baseline
compared with placebo, with a difference in FSG of 1.4 mg/
dl (95% CI 0.3, 2.5, p ¼ 0.011). No other treatment group
comparisons (ezetimibe vs placebo and ezetimibe/statin vs
statins) were statistically signiﬁcantly different (Figure 1).
By week 12 in the ﬁrst-line, long-term studies, the sim-
vastatin and ezetimibe/simvastatin treatment groups in
pooled studies 1A and IB and the simvastatin 80 mg and
ezetimibe/simvastatin 80 mg groups in study II had statis-
tically signiﬁcant changes from baseline in FSG (p <0.05)
with no statistically signiﬁcant differences between treat-
ment groups in either analysis (Figure 1). The change in
FSG increased over time for the simvastatin and ezetimibe/
simvastatin treatment groups through week 36 (maximum
increase: 4.6 mg/dl; 95% CI 3.5, 5.8 and 3.7 mg/dl; 95% CI
2.6, 4.7, respectively) and then decreased at week 60. The
change in FSG increased over time for the simvastatin
80 mg and ezetimibe/simvastatin 80-mg treatment groups
through week 84 (maximum increase: 3.6 mg/dl; 95% CI
2.6, 4.7 and 3.7 mg/dl; 95% CI 2.7, 4.8, respectively) and
then decreased at week 96 (Figure 1).
Increases from baseline in FSG were small in the add-
on studies for the statin (0.2 mg/dl; 95% CI 0.6, 1.0)
compared with ezetimibe þ statin groups (0.5 mg/dl; 95%
CI 0.1, 1.1; p >0.05) and slightly higher for the
ezetimibe þ statin group (1.4 mg/dl; 95% CI 0.6, 2.3)
compared with the statin dose-doubling group (1.1 mg/dl;
95% CI 0.3, 2.0) in the uptitration studies (p <0.05;Figure 2). These changes were similar relative to those
observed in ﬁrst-line studies at 12 weeks in the statin
(0.8 mg/dl; 95% CI 0.3, 1.3) versus ezetimibe/statin
group (1.1 mg/dl; 95% CI 0.6, 1.6). There were no sig-
niﬁcant differences in mean FSG changes between treat-
ment groups (Figure 2).
Among subgroups of patients in ﬁrst-line and second-line
studies with post-baseline FSG <126 and 126 mg/dl,
baseline characteristics were generally similar with some
numerical differences, including higher baseline BMI, FSG,
triglyceride levels, and lower HDL-C levels in subjects with
post-baseline FSG 126 mg/dl compared with subjects with
post-baseline FSG <126 mg/dl (Table 1). Proportions of
patients with FSG 126 mg/dl were overall low and were
highest in the group with baseline FSG 100 to 126 mg/dl
for all treatments in all the ﬁrst-line short-term (Figure 3),
ﬁrst-line long-term (Figure 3), and second-line add-on and
uptitration studies (Figure 3). There were no signiﬁcant
treatment differences between any of the treatment groups in
any of the analyses. Overall, elevated FSG 126 mg/dl did
not appear to be related to increasing age, higher baseline
BMI, FSG, and triglyceride levels and lower HDL-C levels,
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Figure 2. Changes from baseline in FSG in ﬁrst- and second-line studies.
The error bars represent SE. **p<0.05; ns at the 0.05 alpha level (p >0.05).
“
†,” First-line short-term studies: ezetimibe 10 mg (Eze) þ statin versus
statins as described in Figure 1 during 12 weeks. “z,”Second-line add-on
studies: Eze versus placebo for 8 weeks added to on-going statin ¼ ator-
vastatin (10, 20, 40, or 80 mg), cerivastatin (0.2, 0.3, 0.4, or 0.8 mg),
ﬂuvastatin (10, 20, 40, or 80 mg; 1 patient received 160 mg), lovastatin (10,
20, 40, or 80 mg), pravastatin (10, 20, 40, or 80 mg), and simvastatin (10,
20, 40, or 80 mg). “z,”Second-line uptitration studies: Eze 10 mg versus
doubling the statin dose during 6 to 8 weeks. ns ¼ not statistically signif-
icant; Ongoing statin ¼ atorvastatin (10, 20, or 40 mg), then uptitrated to
atorvastatin (20, 40, or 80 mg).
Preventive Cardiology/Glucose Changes With Ezetimibe/Statin in Hypercholesterolemia 1815although there was a trend toward increasing FSG in pa-
tients with higher FSG at baseline (Supplementary
Figure 1).
Of several baseline factors explored, increasing age,
BMI, and baseline FSG, HDL-C, and triglycerides were
associated with very small but statistically signiﬁcant
percent changes from baseline in FSG in univariate analyses
for all ﬁrst-line and second-line uptitration studies
(Supplementary Table 3). In second-line add-on studies,
only BMI was signiﬁcant. Additional signiﬁcant factors
identiﬁed included race, Apo B, and treatment in long-term
studies 1A and 1B, and gender and Apo B in long-term
study II. Because of the very small effect sizes, these fac-
tors were not considered to be clinically meaningful. In
multivariate analysis, age, BMI, and baseline FSG, HDL-C,
and triglycerides remained signiﬁcant factors for the short-
term ﬁrst-line studies, whereas in the ﬁrst-line long-term
studies (IA, IB, and II), all variables (including Apo B) with
the exception of HDL-C and triglycerides remained statis-
tically signiﬁcant; race was additionally signiﬁcant in long-
term studies 1A and 1B. In the second-line add-on studies,
only baseline BMI was associated with a signiﬁcant
decrease in FSG, and thus, multivariate analysis was not
further pursued. In the second-line uptitration studies, age,
BMI, and baseline FSG and triglycerides remained statisti-
cally signiﬁcant when assessed in a multivariable model.
Age and baseline BMI, FSG, triglycerides, and HDL-C did
not appear to be related to changes from baseline in FSG in
the ﬁrst-line and second-line studies (Supplementary
Figure 2) consistent with the very small size effects seen
in univariate analyses. Correlation analysis at the ﬁnal data
points for the ﬁrst-line long-term and second-line study
analyses showed that the magnitude of associations was
small (Supplementary Table 4), indicating no evidence ofclinically meaningful relations between changes in FSG and
changes in LDL-C, BMI, HDL-C, triglycerides, and Apo B.
Correlational analyses were not conducted for the ﬁrst-line
short-term studies.
Discussion
The results of these analyses suggest that the addition of
ezetimibe therapy does not further increase FSG levels
beyond those observed with statin monotherapy for up to
96 weeks of treatment in patients who were statin naive or
on statin therapy at baseline. Both statin monotherapy and
ezetimibe/statin combination therapy were associated with
small, statistically signiﬁcant increases in FSG levels from
baseline that decreased over time. However, no signiﬁcant
effect was observed with ezetimibe monotherapy, and FSG
elevations 126 mg/dl were overall infrequent in all
treatment groups. Baseline factors characteristic of subjects
with the metabolic syndrome or prediabetes, including
numerically higher baseline BMI, baseline FSG and tri-
glyceride levels, and numerically lower baseline HDL-C
levels, were observed in patients with baseline FSG
126 mg/dl versus those with FSG <126 mg/dl; however,
these factors were not related to increased changes from
baseline in FSG. Changes from baseline in LDL-C, BMI,
HDL-C, triglycerides, and Apo B were not related to
changes in FSG.
The results of the present study agree with previous re-
ports of the effects of ezetimibe as monotherapy and com-
bined with statin therapy on glucose metabolism. For
example, a signiﬁcant reduction in insulin resistance and/or
fatty liver was reported for ezetimibe as monotherapy or in
combination with pravastatin in small clinical trials.14e16 In
a recent study including 120 Japanese patients with hyper-
cholesterolemia at moderate to high risk for CVD, 12 weeks
of treatment with ezetimibe combined with statins conferred
a signiﬁcant decrease in HbA1c levels (0.3% from base-
line, p <0.05) and fasting serum insulin levels, although
there was no signiﬁcant difference in glucose levels between
treatments.17 Moutzouri et al18 also reported no signiﬁcant
changes from baseline nor signiﬁcant differences between
groups in FSG, HbA1c, or homeostatic model assessment b-
cell function in a study comparing simvastatin 40 mg,
rosuvastatin 10 mg, and ezetimibe 10 mg/simvastatin
10 mg. Limited data suggest that ezetimibe monotherapy
does not result in dysregulation of glucose metabolism. In
Japanese subjects with type 2 diabetes mellitus, there were
no signiﬁcant differences between ezetimibe and placebo in
changes from baseline in HbA1c, fasting plasma glucose, or
glycoalbumin over 24 weeks of treatment,19 consistent with
the ﬁrst-line, long-term results shown in the present anal-
ysis. Taken together, these results strengthen and conﬁrm
that ezetimibe treatment does not result in dysregulation of
glucose metabolism, either as monotherapy or when added
to a statin.
Although statins have been associated with a slight in-
crease in the incidence of diabetes, the overall beneﬁt of
statins on CVD risk and mortality outweighs this risk.1e3
Moreover, the development of diabetes has been shown to
be more limited in those predisposed to a higher diabetes
risk.20,21 In the present study, numerically higher baseline
Table 1
Baseline characteristics of subjects with fasting plasma glucose <126 mg/dL at baseline in subgroups with post-baseline fasting plasma glucose <126 or
126 mg/dL
Post
baseline
FSG level
[mg/dL]
Treatment
Groups
Number of
subjects
Mean BMI,
kg/m2  SD
Mean FSG,
mg/dL
 SD
Mean
LDL-C,
mg/dL  SD
Median
TG,
mg/dL  SD
Mean
HDL-C,
mg/dL  SD
1st-line short-term studies
All Studies <126 PBO 425 28  5 93  10 178  23 151  75 52  13
Eze 430 28  6 94  9 179  22 154  84 52  13
Statin* 1722 28  5 93  10 179  23 157  77 51  12
EzeþStatin* 1690 28  5 94  93 178  23 157  83 52  13
126 PBO 7 30  3 105  10 179  14 168  43 48  8
Eze 8 31  4 103  13 172  17 188  86 46  5
Statin* 47 31  5 109  13 176  26 165  107 49  11
EzeþStatin* 46 32  6 109  11 176  17 185  81 48  10
1st-line long-term studies
Study 1A <126 All Simva† 208 28  5 93  10 176  25 167  90 49  11
Eze þAll Simva† 277 28  5 93  10 176  27 161  88 52  12
126 All Simva† 7 30  5 113  15 180  34 208  63 45  14
Eze þAll Simva† 5 29  5 115  8 171  18 263  69 42  10
Study 1B <126 All Simva † 406 28  5 92  11 180  25 151  74 51  12
Eze þAll Simva † 392 28  6 92  11 177  25 148  80 53  13
126 All Simva† 10 31  8 106  12 180  31 195  84 53  13
Eze þAll Simva† 7 32  5 114  6 170  27 240  111 44  11
Study II <126 Simva 80 339 27  4 89  9 319  67 158  100 47  12
Eze þ Simva 80 332 27  4 88  8 318  64 154  90 47  11
126 Simva 80 15 28  5 98  13 302  51 192  112 48  13
Eze þ Simva 80 15 35  6 99  14 322  69 194  176 37  8
2nd-line studies
All Add-on studies <126 All Statinz 779 29  5 96  10 139  37 156  75 51  12
Eze þAll Statinz 1365 29  6 97  10 136  34 160  73 49  12
126 All Statinz 14 35  8 104  16 134  52 47  14 145  53
Eze þAll Statinz 24 31  6 112  20 130  32 42  8 160  83
All Uptitration studies <126 Eze þAll Statinx 613 29  5 97  11 102  21 130  53 53  13
Eze þAll Statinx 604 29  4 97  11 103  27 131  55 53  13
126 All Statinx 12 29  4 108  9 96  14 146  71 43  10
Eze þAll Statinx 23 32  6 112  10 97  19 133  54 51  12
BMI ¼ body mass index; Eze ¼ ezetimibe 10 mg; FSG ¼ fasting serum glucose; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density
lipoprotein cholesterol; PBO ¼ placebo; SD ¼ standard deviation; Simva ¼ simvastatin; TC ¼ total cholesterol; TG ¼ triglycerides.
Note: Only subjects with baseline FSG <126 mg/dL are included in this summary table.
* Simvastatin (10, 20, 40, or 80 mg), lovastatin (10, 20, or 40 mg), pravastatin (10, 20, or 40 mg), atorvastatin (10, 20, 40, or 80 mg).
† Simvastatin (10, 20, 40, or 80 mg).
z Ongoing atorvastatin (10, 20, 40, 80 mg), cerivastatin (0.2, 0.3, 0.4, 0.8 mg), ﬂuvastatin (10, 20, 40, 80 mg; 1 patient received 160 mg), lovastatin (10, 20,
40, 80 mg), pravastatin (10, 20, 40, 80 mg), and simvastatin (10, 20, 40, 80 mg).
x Ongoing atorvastatin (10, 20, or 40 mg), then uptitrated to atorvastatin (20, 40, or 80 mg).
1816 The American Journal of Cardiology (www.ajconline.org)BMI, baseline FSG, and triglyceride levels and numerically
lower baseline HDL-C levels were observed in patients with
post-baseline FSG 126 mg/dl versus those with FSG
<126 mg/dl. Although these baseline factors are generally
characteristic of subjects with the metabolic syndrome or
prediabetes, none were shown to be related to increased
changes from baseline in FSG in this study. Conversely, a
trial that compared high-dose atorvastatin with placebo
demonstrated that baseline FSG level and features of the
metabolic syndrome were predictive of new-onset type 2
diabetes.21 A later analysis showed that the incidence of
new-onset diabetes increased with atorvastatin 80 mg/day
compared with low-dose statin therapy in patients with
higher numbers of baseline diabetes risk factors (FSG
>100 mg/dl, triglycerides >150 mg/dl, BMI >30 kg/m2,
history of hypertension).22 Preiss et al1 showed that theincidence of new-onset diabetes mellitus and CVD events at
moderate- and high-dose statins were similar across sub-
groups of age and baseline HDL-C, BMI, and FSG. A
meta-regression analysis demonstrated that age was associ-
ated with the risk of incident diabetes with stronger
statin-attributable risk found in studies with elderly pa-
tients.3 Statin use resulted in signiﬁcant FSG increases in
patients with (7 mg/dl) and without diabetes (2 mg/dl),
although this increase in FSG was not related to age.23 Of
note, these other trials assessed statins and not ezetimibe,
making comparison between this and the other trials difﬁ-
cult. However, additional study is needed to illuminate the
baseline factors that may play a role in new-onset diabetes
during treatment for dyslipidemia.
Studies have shown that statin use has been associated
with small increases in FSG, which may vary depending on
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Figure 3. Proportion of subjects with FSG 126 mg/dl with baseline FSG <126, <100, and 100 to 126 mg/dl. Error bars represent 95% CIs. “†,” Odds
ratios (ORs) for treatment comparisons based on logistic regression adjusted for treatment, study, and baseline FSG; all comparisons are p >0.05 in the overall
(<126 mg/dl), <100, and 100 to 126 mg/dl subgroups. (A) First-line short-term studies: ezetimibe 10 mg (Eze); placebo and statin as described in Figure 1.
ORs for Eze versus placebo, statin versus placebo, and Eze þ statin versus statin treatment comparisons. (B) First-line long-term studies: all simvastatin
(Simva) and Eze þ Simva as described in Figure 1, Simva 80 mg and Eze/Simva 80 mg. (C) Second-line studies. Add-on: Eze or placebo added to ongoing
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1818 The American Journal of Cardiology (www.ajconline.org)the statin (i.e., lipophilicity, potency).24,25 The underlying
cause of statin-induced glucose dysregulation is unclear,
although several potential mechanisms have been proposed,
including LDL-C lowering.1,24e30 This is supported by
Mendelian genetics, suggesting that new-onset diabetes is
related partly to inhibition of HMG CoA reductase and is
inversely associated with LDL-C levels.31,32 However, in
our analysis, LDL-C reduction was not related to increased
FSG, consistent with a previous study showing that the
magnitude of LDL-C reduction by various statins and doses
did not inﬂuence the development of diabetes.25 It should
be noted that bile acidebinding resins that reduce LDL-C
also lower FSG and HbA1c.33 Moreover, recent genetic
analyses suggest that inhibition of HMG CoA reductase, the
target of statin therapy, is partly related to increased gly-
cemic burden, whereas the LDL-C lowering and CVD risk
reduction effects of NPC1L1 are not.34 These ﬁndings
support our results, which demonstrated that ezetimibe did
not increase FSG levels more than statins alone.35 Consis-
tent with this, there was no increase in the incidence of
new-onset diabetes with ezetimibe/simvastatin compared
with simvastatin in the recently reported Improved Reduc-
tion of Outcomes: Vytorin Efﬁcacy International Trial.6,36
Our study has some limitations. This was a post hoc
analysis of pooled clinical trial data, and thus, the results
are considered to be hypothesis generating. The analyses
were conducted across doses; therefore, the effects of the
statin intensity included in the trials were not evaluated. In
the present study, FSG data were assessed; however, pa-
tient information including the diagnoses of diabetes,
changes in weight and HBA1c levels, and the initiation of
glucose-lowering medications during the trial were not
consistently available to evaluate new-onset diabetes mel-
litus. Nonetheless, FSG is an important marker of type 2
diabetes mellitus recommended for screening of patients
with CVD.3 Although our study did not demonstrate a
statistically signiﬁcant effect of adding ezetimibe on FSG
levels, it is possible that because of small sample sizes,
there may have been inadequate power in some treatment
groups to detect additional effects. Additionally, it was
unclear as to what role baseline factors may have played in
new-onset diabetes during treatment for dyslipidemia. It
was also not feasible to evaluate glycemic effects in pa-
tients with diabetes in our analysis because of incomplete
anti-diabetic medication histories. Although one of our
studies included HeFH patients who have been shown to
have a lower incidence of insulin resistance or diabetes
than the general population and a low rate of new-onset
diabetes with statin therapy, which could have affected
the results of the analyses,37,38 the results were generally
similar across all study types, suggesting that HeFH is not
associated with increased FSG.
In conclusion, these data suggest that statin therapy is
associated with small increases in FSG and that addition of
ezetimibe therapy does not further increase FSG levels
beyond those observed with statin therapy up to 60 weeks in
subjects with hypercholesterolemia or up to 96 weeks of
treatment in subjects with heterozygous familial hypercho-
lesterolemia, when co-administered in patients who are
statin naive or those on stable statin therapy.Acknowledgments: The authors would like to thank Carol
Zecca, BS and Jennifer Rotonda, PhD, Merck & Co., Inc.
for editorial assistance.
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